Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Philadelphia_chromosome-positive_leukemia
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Sprycel
|
| gptkbp:class |
tyrosine kinase inhibitor
|
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:effective_date |
gptkb:2006
|
| https://www.w3.org/2000/01/rdf-schema#label |
dasatinib
|
| gptkbp:ingredients |
C22 H26 Cl N5 O2 S
|
| gptkbp:is_atype_of |
L01 E A01
|
| gptkbp:is_used_for |
gptkb:chronic_myeloid_leukemia
gptkb:healthcare_organization |
| gptkbp:lifespan |
3 to 5 hours
|
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
liver
|
| gptkbp:nutritional_value |
over 90%
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea rash |
| gptkbp:targets |
gptkb:BCR-ABL_tyrosine_kinase
|
| gptkbp:type_of |
302962-49-8
|
| gptkbp:weight |
488.99 g/mol
|